Skip to main content
    E

    enVVeno Medical Corp (NVNO)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $5.95
    -0.23 (-3.65%)

    Market Cap: $4.29M

    Last updated: Nov 17, 2026 at 11:01 AM ET

    enVVeno Medical Corp (NVNO) Financials: Revenue, Profit and Cash Flow

    Updated Oct 29, 2026. Financial statements from company filings, amounts in US dollars.

    enVVeno Medical reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$19.47M, operating cash flow was -$15.57M and free cash flow was -$15.57M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$4.37M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $20.90M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0-100.0%N/AN/AN/A
    Dec 2019$31.24K-83.3%100.0%-24566.5%-24406.7%
    Dec 2018$186.55K-55.8%100.0%-4210.5%-6991.5%
    Dec 2017$422.11K-46.3%0.6%-1445.9%-1845.8%
    Dec 2016$785.91KN/A-22.3%-592.8%-749.0%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$0$0$0$0$0$0$31.24K$186.55K$422.11K$785.91K
    Cost of revenue$0$0$0$0$0$0$0$0$419.66K$961.47K
    Gross profit$0$0$0$0$0$0$31.24K$186.55K$2.45K-$175.56K
    Research and development$9.98M$12.25M$13.58M$9.91M$5.73M$4.25M$2.21M$1.24M$649.74K$0
    Operating income-$20.90M-$23.83M-$25.24M-$24.93M-$16.89M-$9.14M-$7.68M-$7.85M-$6.10M-$4.66M
    Net income-$19.47M-$21.82M-$23.52M-$24.67M-$16.53M-$9.14M-$7.63M-$13.04M-$7.79M-$5.89M
    EBITDA-$19.68M-$21.68M-$23.15M-$24.30M-$16.41M-$8.76M-$7.28M-$966.97K-$4.28MN/A
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$812.00K$0$0$0$824.00K
    Gross profit$0$0$0-$117.00K$0$0$0-$122.00K$0$0$0-$134.00K
    Operating income-$4.53M-$3.80M-$4.06M-$4.01M-$4.88M-$7.05M-$4.95M-$6.70M-$6.17M-$5.45M-$5.50M-$6.28M
    Net income-$4.37M-$3.60M-$3.85M-$3.74M-$4.54M-$6.69M-$4.50M-$6.23M-$5.64M-$4.96M-$4.99M-$5.65M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $390.00K by $2.67M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$29.56M$44.95M$48.63M$41.66M$57.70M$10.54M$3.43M$3.56M$2.21M$1.78M
    Current assets$28.83M$43.73M$46.92M$39.44M$55.04M$9.57M$1.42M$2.84M$170.41K$393.22K
    Cash and equivalents$3.06M$1.75M$3.62M$4.55M$54.73M$9.33M$1.31M$2.74M$77.69K$56.51K
    Total liabilities$2.43M$2.79M$2.44M$2.93M$3.29M$3.44M$2.44M$1.52M$8.17M$2.07M
    Short-term debt$390.00K$364.00K$338.00K$314.00K$291.00K$312.70K$0$26.98K$2.12M$632.77K
    Long-term debtN/AN/AN/AN/AN/AN/AN/AN/A$499.00KN/A
    Shareholder equity$27.13M$42.16M$46.20M$38.73M$54.40M$7.10M$989.94K$2.04M-$11.13M-$4.22M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$19.49M$22.66M$26.10M$29.56M$32.35M$36.58M$40.58M$44.95M$50.39M$40.99M$44.83M$48.63M
    Total liabilities$2.59M$1.99M$2.35M$2.43M$2.90M$3.52M$2.27M$2.79M$3.02M$2.58M$2.46M$2.44M
    Cash and equivalents$2.58M$2.84M$2.60M$3.06M$1.54M$2.04M$2.94M$1.75M$17.91M$2.38M$2.31M$3.62M
    Shareholder equity$16.90M$20.67M$23.75M$27.13M$29.45M$33.06M$38.31M$42.16M$47.37M$38.42M$42.37M$46.20M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$15.57M-$16.84M-$18.86M-$15.62M-$11.85M-$7.68M-$5.90M-$6.36M-$4.20M-$3.08M
    Capital expenditures$5.00K$37.00K$33.00K$115.00K$368.00K$180.29K$363.89K$12.42K$170.94K$373.62K
    Free cash flow-$15.57M-$16.88M-$18.89M-$15.73M-$12.22M-$7.86M-$6.26M-$6.37M-$4.37M-$3.46M
    Investing cash flow$15.86M$1.33M-$7.87M-$34.55M-$368.00K-$180.29K-$363.89K-$12.42K$165.31K-$705.27K
    Financing cash flow$1.02M$13.64M$25.79M$0$57.61M$15.07M$5.64M$9.03M$4.06M$2.26M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$3.18M-$3.55M-$3.24M-$3.44M-$4.39M-$3.71M-$4.02M-$5.11M-$4.28M-$3.91M-$3.55M-$4.97M
    Capital expendituresN/AN/A$0$0$5.00K$5.00K$5.00K$4.00K$9.00K$14.00K$10.00K$4.00K
    Free cash flowN/AN/A-$3.24M-$3.44M-$4.40M-$3.72M-$4.02M-$5.11M-$4.29M-$3.92M-$3.56M-$4.98M
    Last 12 quarters

    Frequently Asked Questions About NVNO

    What is enVVeno Medical's annual revenue?

    enVVeno Medical reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is enVVeno Medical profitable?

    No. enVVeno Medical reported net income of -$19.47M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does NVNO generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$15.57M minus capital expenditures of $5.00K produced free cash flow of -$15.57M.

    How much debt does enVVeno Medical have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $390.00K and cash and equivalents of $3.06M.